3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
9
atezolizumab
8
Drug Therapy
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Radiotherapy
4
Paclitaxel
4
Interleukin-2
4
Cyclophosphamide
4
Docetaxel
3
fludarabine phosphate
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Radiation
2
Patient Reported Outcome Measures
2
Oncolytic Virotherapy
2
Ipilimumab
2
Immunotherapy
2
Gemcitabine
2
Filgrastim
2
Cisplatin
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Patient-Specific Modeling
×
Dermatologic
×
Clear all
NCT02000739
2014-07-14
GENIUS
Dartmouth-Hitchcock Medical Center
Phase 4
Withdrawn